

CITATION REPORT

List of articles citing

Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial

DOI: 10.1016/s0140-6736(02)11024-5
Lancet, The, 2002, 360, 895-900.

Source: <https://exaly.com/paper-pdf/34205709/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
682	[Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure]. 2002 , 56, 665-72		11
681	Estradiol valerate/levonorgestrel: no pharmacokinetic interaction with selegiline. 2002 , &NA;, 15		
680	[Cardio-vascular effects of sildenafil: new data]. 2002 , 51, 341-5		3
679	Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists. 2003 , 4, 457-65		69
678	Erectile dysfunction in the cardiac patient. 2003 , 4, 466-71		16
677	[Drug therapy of erectile dysfunction--the current status]. 2003 , 42, 1322-9		2
676	Intravenous sildenafil and inhaled nitric oxide: a randomised trial in infants after cardiac surgery. 2003 , 29, 1996-2003		157
675	Pulmonary hypertension in systemic sclerosis. 2003 , 29, 335-49, vii		55
674	Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. 2003 , 78, 1207-13		91
673	[Diagnosis and treatment of diffuse interstitial lung diseases]. 2003 , 39, 580-600		55
672	Emerging therapies for pulmonary hypertension: striving for efficacy and safety. 2003 , 41, 2126-9		7
671	Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. 2003 , 42, 158-64		290
670	Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. 2003 , 108, 239-44		124
669	Non erectile dysfunction application of sildenafil. 2003 , 28, 325-33		10
668	[Sex, erectile dysfunction, and the heart: a growing problem]. 2003 , 28, 284-90		20
667	Sildenafil for lung fibrosis and pulmonary hypertension. <i>Lancet, The</i> , 2003 , 361, 262-3; author reply 263 40		4
666	[Treatment of primary pulmonary hypertension with vasodilator drugs]. 2003 , 120, 194-6		

665	Long-term use of sildenafil. 2003 , 4, 397-405	89
664	Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. 2003 , 108 Suppl 1, II167-73	85
663	Pulmonary hypertension in chronic obstructive pulmonary disease. 2003 , 21, 892-905	301
662	Detection of intrapulmonary concentration of lopinavir in an HIV-infected patient. 2003 , 17, 1710-1	18
661	Treatment of pulmonary hypertension. 2003 , 326, 835-6	20
660	The diagnostic yield of stool analysis in 525 HIV-1-infected individuals. 2003 , 17, 1711-3	9
659	Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. 2003 , 167, 1139-41	211
658	Pathophysiology and pharmacological treatment of pulmonary hypertension in acute respiratory distress syndrome. 2003 , 21, 720-7	94
657	Long-time survival with HIV-related pulmonary arterial hypertension: a case report. 2003 , 17, 1714-5	21
656	Pathophysiology of pulmonary hypertension due to lung disease. 2003 , 9, 131-8	43
655	Management of pulmonary hypertension resulting from interstitial lung disease. 2003 , 9, 426-30	31
654	A manic episode associated with efavirenz therapy for HIV infection. 2003 , 17, 1713-4	16
653	An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy. 2003 , 10, 99-107	103
652	Sequential cutaneous drug reactions to protease inhibitors in the context of occupational post-exposure prophylaxis. 2003 , 17, 1709	3
651	Current World Literature. 2003 , 14, 201-212	
650	Current World Literature. 2003 , 12, 323-346	
649	Current World Literature. 2003 , 12, 559-575	
648	Current world literature. 2003 , 16, 349-65	

647	Linezolid: the first oxazolidinone antimicrobial. 2003 , 139, 863; author reply 864	
646	Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the raynaud phenomenon. 2003 , 139, 871-3	56
645	Linezolid: The First Oxazolidinone Antimicrobial. 2003 , 139, 864	4
644	References. 601-868	
643	Chemotherapy in women with breast cancer. 2003 , 139, 867-8; author reply 868-9; discussion 869	
642	Chemotherapy in women with breast cancer. 2003 , 139, 868; author reply 868-9	5
641	Chemotherapy in Women with Breast Cancer. 2003 , 139, 869	1
640	Linezolid: the first oxazolidinone antimicrobial. 2003 , 139, 863; author reply 864	1
639	Association of high serum ferritin concentration with glucose intolerance and insulin resistance in healthy people. 2003 , 139, 869-71	61
638	Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease. 2003 , 139, 864	
637	A rash decision. 2003 , 139, 869	3
636	Inhaled corticosteroids in chronic obstructive pulmonary disease. 2003 , 139, 864; author reply 864-5	2
635	Treatment of Pulmonary Arterial Hypertension with Sildenafil. 2004 , 39, 243-253	2
634	Rosiglitazone for Treatment of HIV Lipodystrophy. 2004 , 141, 739	
633	To Butterfly or To Needle: The Specimen Testing Question. 2004 , 141, W-140	1
632	Low-Carbohydrate Diets. 2004 , 141, 738	
631	Residents' work hours. 2004 , 141, 740; author reply 742	
630	Tadalafil in primary pulmonary arterial hypertension. 2004 , 141, 743-4	40

629	Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. 2004 , 170, 360-5	166
628	Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. 2004 , 109, 3106-11	225
627	Postnatal maturation of phosphodiesterase 5 (PDE5) in piglet pulmonary arteries: activity, expression, effects of PDE5 inhibitors, and role of the nitric oxide/cyclic GMP pathway. 2004 , 56, 563-70	23
626	Sildenafil, nitric oxide, and acute lung injury: pathophysiology beats pharmacotherapy?. 2004 , 55, 370-1	9
625	Acute respiratory distress syndrome (ARDS). 2004 , 15, 37-42	
624	Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. 2004 , 169, 39-45	207
623	Alternatives to nitric oxide. 2004 , 70, 119-31	22
622	Tadalafil: A Comprehensive Update. 2004 , 2, 225-246	
621	Natriuretic peptides, respiratory disease, and the right heart. 2004 , 126, 1330-6	119
620	Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway. 2004 , 44, 596-600	13
619	Prostacyclin and its analogues in the treatment of pulmonary hypertension. 2004 , 102, 139-53	102
618	Phosphodiesterase inhibitors in the management of primary pulmonary hypertension. 2004 , 19, 74-9	1
617	Pulmonary hypertension. 2004 , 29, 575-634	16
616	Regenerative medicine in andrology: Tissue engineering and gene therapy as potential treatment options for penile deformations and erectile dysfunction. 2004 , 46, 162-9	13
615	Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. 2004 , 94, 1475-7	107
614	Scleroderma--clinical and pathological advances. 2004 , 18, 271-90	79
613	B-type natriuretic Peptide and the right heart. 2004 , 9, 99-105	21
612	Therapie der pulmonalen Hypertonie. 2004 , 1, 95-101	2

611	[Pulmonary hypertension. Pathophysiology and current concepts of medication therapy]. 2004 , 53, 734-40	2
610	Acute right ventricular failure--from pathophysiology to new treatments. 2004 , 30, 185-196	163
609	Type 5 phosphodiesterase inhibition in heart failure and pulmonary hypertension. 2004 , 1, 183-9	24
608	Severe pulmonary hypertension: a frequent complication of stem cell transplantation for malignant infantile osteopetrosis. 2004 , 124, 63-71	55
607	Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. 2004 , 10, 945-50	63
606	Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. 2004 , 25, 2243-78	665
605	A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. 2004 , 169, 34-8	90
604	Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. 2004 , 25, 431-6	75
603	Actualité sur l'hypertension artérielle pulmonaire (HTAP) « idiopathique ». <i>Revue Des Maladies Respiratoires</i> , 2004 , 21, 82-85	0
602	Actualité sur l'hypertension artérielle pulmonaire [Exclusion de l'hypertension artérielle pulmonaire idiopathique. <i>Revue Des Maladies Respiratoires</i> , 2004 , 21, 76-81	0
601	[Evidence based pneumology: 3rd update workshop to the SPLF. Idiopathic diffuse interstitial pneumopathies]. <i>Revue Des Maladies Respiratoires</i> , 2004 , 21, 1183-6	0 0
600	Traitement de l'hypertension artérielle pulmonaire de l'enfant. 2004 , 11, 945-945	
599	Hypertension artérielle pulmonaire. 2004 , 1, 46-68	0
598	Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. 2004 , 43, 685-725	108
597	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. 2004 , 44, 1488-96	86
596	Sildenafil for pulmonary hypertension. 2004 , CD003562	12
595	Treatment of pulmonary arterial hypertension. 2004 , 351, 1425-36	1338
594	New treatment options for erectile dysfunction in patients with diabetes mellitus. 2004 , 64, 2667-88	69

593	Pulmonary arterial hypertension in systemic sclerosis: clinical manifestations, pathophysiology, evaluation, and management. 2004 , 3, 339-52	39
592	Sildenafil. 2004 ,	
591	Diagnosis and treatment of pulmonary arterial hypertension. 2004 , 22, 441-52, vii	5
590	Could the consequences of premature delivery be further attenuated by means of new prenatal strategies?. 2004 , 117 Suppl 1, S21-4	3
589	[Treatments for pulmonary arterial hypertension]. 2004 , 25, 720-31	2
588	Idiopathic pulmonary arterial hypertension: current state of play and new treatment modalities. 2004 , 97 Suppl 1, 7-10	15
587	[Treatment of pulmonary arterial hypertension in children]. 2004 , 11, 945-50	8
586	Sildenafil: emerging cardiovascular indications. 2004 , 78, 1496-506	53
585	Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. 2004 , 125, 580-6	100
584	Treatment of rebound and chronic pulmonary hypertension with oral sildenafil in an infant with congenital diaphragmatic hernia. 2004 , 5, 184-7	47
583	Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertensionA randomized prospective study. 2004 , 44, 1488-1496	255
582	Normal pulmonary capillary blood volume in patients with chronic infiltrative lung disease and high pulmonary artery pressure. 2004 , 126, 1460-6	13
581	What you should know about pulmonary hypertension. 2004 , 29, 8-15, 19; quiz 20-1	5
580	Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial. 2004 , 141, 169-77	220
579	A 31-year-old pregnant woman with progressive exertional dyspnea and differential cyanosis. 2004 , 126, 638-41	8
578	Sildenafil for enhanced performance at high altitude?. 2004 , 141, 233-5	11
577	Autonomic control of the cardiovascular system during acclimatization to high altitude: effects of sildenafil. 2004 , 97, 935-40	57
576	Pulmonary Arterial Hypertension in Connective Tissue Disease. 2004 , 45-62	1

575	A Case of Pulmonary Hypertension Associated With a Rare Congenital Hemolytic Anemia. 2005 , 12, 319-322	
574	Inhaled alternatives to nitric oxide. 2005 , 33, S188-95	27
573	Pulmonary hypertension in interstitial lung disease. 2005 , 11, 452-5	46
572	Addition of oral sildenafil to beraprost is a safe and effective therapeutic option for patients with pulmonary hypertension. 2005 , 45, 286-9	33
571	Endothelin receptor antagonists: clinical realities and future directions. 2005 , 45, 182-91	36
570	Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. 2005 , 69, 461-5	45
569	Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. 2006 , 61, 68-74	233
568	Current treatment strategies for pulmonary arterial hypertension. 2005 , 258, 199-215	51
567	Inhibition of RhoA/Rho kinase pathway is involved in the beneficial effect of sildenafil on pulmonary hypertension. 2005 , 146, 1010-8	120
566	Lack of synergistic effect of molsidomine and sildenafil on development of pulmonary hypertension in chronic hypoxic rats. 2005 , 510, 87-96	16
565	Early haemodynamic benefit of sildenafil in patients with coexisting chronic thromboembolic pulmonary hypertension and left ventricular dysfunction. 2005 , 42, 41-5	33
564	[Therapy of pulmonary arterial hypertension]. 2005 , 46, 341-9	0
563	Current therapy of pulmonary hypertension. 2005 , 30, 303-10	4
562	[Emerging therapies for the treatment of pulmonary arterial hypertension]. 2005 , 30, 296-302	1
561	[New aspects in the diagnosis and therapy of acute and chronic pulmonary hypertension]. 2005 , 30, 257-60	
560	Is sildenafil effective in secondary pulmonary hypertension due to systemic lupus erythematosus? A case report. 2005 , 24, 671-2	2
559	Long-term therapy of interferon-alpha induced pulmonary arterial hypertension with different PDE-5 inhibitors: a case report. 2005 , 3, 26	26
558	Sildenafil and an early stage of chronic hypoxia-induced pulmonary hypertension in newborn piglets. 2005 , 40, 72-80	13

557	Therapie der erektilen Dysfunktion. 2005 , 341-352		
556	One-year follow-up of the effects of sildenafil on pulmonary arterial hypertension and veno-occlusive disease. 2005 , 38, 185-95		36
555	Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. 2005 , 25, 783-8		220
554	Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-label, pilot study. 2005 , 111, 3274-80		203
553	Pulmonary arterial hypertension: are we doing enough to identify systemic sclerosis patients at high risk of this rare condition?. 2005 , 44, 141-2		11
552	Oral sildenafil for treatment of severe pulmonary hypertension in an infant. 2005 , 88, 109-12		24
551	Treatment of pulmonary hypertension in the general adult intensive care unit: a role for oral sildenafil?. <i>British Journal of Anaesthesia</i> , 2005 , 94, 774-7	5-4	24
550	Pulmonary fibrosis. 2005 , 117, 3-44		25
549	Prostanoids and phosphodiesterase inhibitors in experimental pulmonary hypertension. 2005 , 67, 251-84		8
548	Severe paediatric pulmonary hypertension: new management strategies. 2005 , 90, 92-8		48
547	Sildenafil: efficacy, safety, tolerability and mechanism of action in treating erectile dysfunction. 2005 , 1, 283-93		34
546	Sildenafil inhibits altitude-induced hypoxemia and pulmonary hypertension. 2005 , 171, 275-81		193
545	Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. 2005 , 127, 1647-53		183
544	Pathogenesis and natural history of usual interstitial pneumonia: the whole story or the last chapter of a long novel. 2005 , 128, 526S-532S		102
543	Cor pulmonale. Etiopatogenia. Proceso diagn?stico. Criterios pron?sticos. Tratamiento. 2005 , 9, 2873-2878		
542	[Treatment of pulmonary arterial hypertension]. 2005 , 34, 1445-55		2
541	Sildenafil citrate and sildenafil nitrate (NCX 911) are potent inhibitors of superoxide formation and gp91phox expression in porcine pulmonary artery endothelial cells. 2005 , 146, 109-17		64
540	Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. 2005 , 172, 105-13		266

539	Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. 2005 , 32, 419-29, vi		34
538	Sildenafil for pulmonary hypertension. 2005 , 39, 869-84		34
537	[Pulmonary arterial hypertension]. <i>Revue Des Maladies Respiratoires</i> , 2005 , 22, 651-66	o	14
536	Prise en charge de l'hypertension artérielle pulmonaire secondaire aux maladies respiratoires. <i>Revue Des Maladies Respiratoires</i> , 2005 , 22, 79-82	o	1
535	[Drug treatments for idiopathic pulmonary fibrosis]. 2005 , 61, 221-31		4
534	Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. 2005 , 99, 91-5		57
533	High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. 2005 , 334, 930-8		165
532	Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. 2005 , 24, 1269-74		116
531	Life after PDE4: overcoming adverse events with dual-specificity phosphodiesterase inhibitors. 2005 , 5, 238-44		88
530	Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension. 2005 , 99, 1501-10		70
529	Oral sildenafil reduces pulmonary hypertension after cardiac surgery. 2005 , 79, 194-7; discussion 194-7		108
528	[Guidelines on diagnosis and treatment of pulmonary arterial hypertension]. 2005 , 58, 523-66		21
527	Lung vasodilatory response to inhaled iloprost in experimental pulmonary hypertension: amplification by different type phosphodiesterase inhibitors. 2005 , 6, 76		25
526	Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. 2005 , 4, 531-40		18
525	Guías de Práctica Clínica sobre el diagnóstico y tratamiento de la hipertensión arterial pulmonar. 2005 , 58, 523-566		
524	Le sildenafil améliore les capacités d'exercice en condition hypoxique et hypobarique. <i>Revue Des Maladies Respiratoires</i> , 2005 , 22, 93-94	o	2
523	Imatinib for the treatment of pulmonary arterial hypertension. 2005 , 353, 1412-3		377
522	L'insuffisance cardiaque aiguë. 2006 ,		

521	Idiopathic pulmonary fibrosis : new concepts in pathogenesis and implications for drug therapy. 2006 , 5, 325-42	39
520	Present and future treatment strategies for pulmonary arterial hypertension : focus on phosphodiesterase-5 inhibitors. 2006 , 5, 271-82	8
519	Therapeutic management of idiopathic pulmonary fibrosis: an evidence-based approach. 2006 , 27, S27-35, vi	9
518	Sildenafil, a PDE5 inhibitor, in the treatment of pulmonary hypertension. 2006 , 4, 293-300	41
517	Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?. 2006 , 22, 2567-74	22
516	Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. 2006 , 20, 722-35	22
515	Pulmonary hypertension in children: the twenty-first century. 2006 , 53, 961-87, x	85
514	Que faire des formes graves de pneumopathies infiltrantes diffuses (exacerbations aiguës, insuffisance respiratoire chronique sévère) : place des nouveaux traitements, indications de transplantation. <i>Revue Des Maladies Respiratoires</i> , 2006 , 23, 92-100	0
513	[Regenerative medicine in andrology: tissue engineering and gene therapy as potential treatment options for penile deformations and erectile dysfunction]. 2006 , 30, 801-11	1
512	Sildenafil Treatment of Unilateral Pulmonary Edema and Pulmonary Hypertension in Pulmonary Artery Agenesis. 2006 , 59, 1347-1349	
511	Edema de pulmón unilateral e hipertensión pulmonar tratada con sildenafilo en la agenesia de la arteria pulmonar. 2006 , 59, 1347-1349	3
510	Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. 2006 , 117, 1077-83	253
509	What role does the right side of the heart play in circulation?. 2006 , 10 Suppl 3, S5	16
508	Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. 2006 , 81, 272-8	51
507	Effects of phosphodiesterase 5 inhibitor on pulmonary vascular reactivity in the fetal lamb. 2006 , 81, 935-42	19
506	Systemic and localized scleroderma. 2006 , 24, 374-92	98
505	Pulmonary hypertension in children. 2006 , 16, 237-247	11
504	Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. 2006 , 166, 231-3	67

503	Sildenafil improves hemodynamic parameters in COPD--an investigation of six patients. 2006 , 19, 386-90	60
502	Treatments for pulmonary arterial hypertension. 2006 , 100, 765-74	11
501	Clinical review: idiopathic pulmonary fibrosis--past, present and future. 2006 , 100, 1871-85	33
500	Fibrose pulmonar idiopática: uma década de progressos. 2006 , 32, 249-260	1
499	Pulmonary Arterial Hypertension. 2006 , 795-821	
498	Efeitos do óxido nítrico inalatório na hipertensão pulmonar de pacientes após cirurgia valvar mitral. 2006 , 21, 136-142	1
497	Upregulated neurohumoral factors are associated with left ventricular remodeling and poor prognosis in rats with monocrotaline-induced pulmonary arterial hypertension. 2006 , 70, 1208-15	38
496	Hypertension artérielle pulmonaire. 2006 , 3, 1-27	2
495	Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. 2006 , 34, 2287-93	216
494	Dose response of intravenous sildenafil on systemic and regional hemodynamics in hypoxic neonatal piglets. 2006 , 26, 99-106	12
493	An evidence-based approach to the management of pulmonary arterial hypertension. 2006 , 21, 385-92	27
492	Abnormal vascular tone in infants and children with lung hypoplasia: Findings from cardiac catheterization and the response to chronic therapy. 2006 , 7, 589-94	40
491	Successful use of surfactant to treat severe intrapulmonary hemorrhage after iatrogenic lung injury--A case report. 2006 , 7, 583-5	10
490	Experimental therapies for hypoxia-induced pulmonary hypertension during acute lung injury. 2006 , 25, 214-26	19
489	Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia. 2006 , 100, 2031-40	104
488	Use of extracorporeal membrane oxygenation to manage post-partum pulmonary haemorrhage associated with pulmonary hypertension and aberrant right pulmonary artery. 2006 , 46, 556-8	3
487	Hypoxic pulmonary hypertension (HPH) and iptakalim, a novel ATP-sensitive potassium channel opener targeting smaller arteries in hypertension. 2005 , 23, 293-316	14
486	Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. 2006 , 5, 689-702	366

485	Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil. 2006 , 18, 251-7	16
484	Long-term vardenafil therapy improves hemodynamics in patients with pulmonary hypertension. 2006 , 29, 123-8	25
483	New insights in the treatment strategy for pulmonary arterial hypertension. 2006 , 20, 377-86	23
482	Dramatic beneficial effects of sildenafil in recurrent massive pulmonary embolism. 2006 , 32, 452-4	21
481	Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports. 2006 , 26, 270-3	13
480	[Pulmonary hypertension: the future has begun]. 2006 , 101, 328-33	1
479	A potential role for sildenafil in the management of pulmonary hypertension in patients with parenchymal lung disease. 2006 , 44, 372-6	76
478	[Beneficial effect of sildenafil following surgery for mitral stenosis complicated by pre-capillary pulmonary hypertension: report of two cases]. 2006 , 55, 286-90	1
477	Respiratory medicine: anti-IgE therapy, lung cancer and pulmonary hypertension. 2006 , 34, 431-434	1
476	Effect of oral sildenafil citrate on intraoperative hemodynamics in patients with pulmonary hypertension undergoing valvular heart surgery. 2006 , 132, 1420-5	31
475	Relaxant effects of the soluble guanylate cyclase activator and NO sensitizer YC-1 in piglet pulmonary arteries. 2006 , 90, 66-72	3
474	Pulmonale Hypertonie im Kindesalter. 2006 , 2, 177-193	
473	[Reverse remodeling -- paradigm shift in the treatment of pulmonary hypertension]. 2006 , 131, 871-4	2
472	Overview of lung transplantation and criteria for selection of candidates. 2006 , 27, 441-69	30
471	A double-blind, placebo-controlled, crossover study of sildenafil in obstructive sleep apnea. 2006 , 166, 1763-7	41
470	[Diagnosis and treatment of pulmonary hypertension]. 2006 , 60, 428-40; quiz 441-2	2
469	Treatment of idiopathic pulmonary fibrosis. 2006 , 27, 668-76	12
468	[Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors]. 2006 , 131, S311-4	6

467	Usual interstitial pneumonia. 2006 , 27, 634-51	37
466	[Diagnosis and therapy of chronic pulmonary hypertension]. 2006 , 60, 749-71	27
465	Sildenafil for pulmonary arterial hypertension. 2006 , 2, 137-43	1
464	Brain natriuretic peptide is a prognostic parameter in chronic lung disease. 2006 , 173, 744-50	203
463	Cardiovascular effects of phosphodiesterase 5 inhibitors. 2006 , 12, 3485-94	45
462	Hypoxia- and non-hypoxia-related pulmonary hypertension - established and new therapies. 2006 , 72, 30-40	36
461	Presentation, survival prospects, and predictors of death in Eisenmenger syndrome: a combined retrospective and case-control study. 2006 , 27, 1737-42	222
460	Chronic Thromboembolic Pulmonary Hypertension-Therapeutic Options. 2006 , 2, 431-438	3
459	Sildenafil improves dynamic vascular function in the brain: studies in patients with pulmonary hypertension. 2006 , 21, 194-200	46
458	Intravenous sildenafil as an effective treatment of pulmonary hypertensive crises during acute intestinal malabsorption. 2006 , 16, 84-6	13
457	Pulmonary Hypertension Secondary to Chronic Respiratory Disease. 2006 , 143-156	
456	Portopulmonary Hypertension. 2006 , 132-142	1
455	Sildenafil for pulmonary arterial hypertension: when blue turns into white. 2006 , 7, 1801-10	4
454	Role of endothelin-1 in exposure to high altitude: Acute Mountain Sickness and Endothelin-1 (ACME-1) study. 2006 , 114, 1410-6	97
453	Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. 2006 , 174, 1042-7	146
452	Effects of sildenafil on exercise capacity in hypoxic normal subjects. 2007 , 8, 155-63	59
451	Chronic sildenafil lowers transpulmonary gradient and improves cardiac output allowing successful heart transplantation. 2007 , 9, 674-7	54
450	PDE-5 inhibitor donor intravenous preconditioning is superior to supplementation in standard preservation solution in experimental lung transplantation. 2007 , 32, 42-7	8

449	Pulmonary hypertension in idiopathic pulmonary fibrosis. 2007 , 132, 998-1006	191
448	Model of chronic adaptation: right ventricular function in Eisenmenger syndrome. 2007 , 9, H54-H60	31
447	Idiopathic pulmonary fibrosis. 2007 , 1, 377-89	7
446	Expert opinion on available options treating pulmonary arterial hypertension. 2007 , 8, 2247-65	30
445	Pulmonary diseases and the heart. 2007 , 116, 2992-3005	146
444	Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. 2007 , 30, 715-21	245
443	Phosphodiesterase 1 upregulation in pulmonary arterial hypertension: target for reverse-remodeling therapy. 2007 , 115, 2331-9	118
442	Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. 2007 , 175, 875-80	168
441	Safety and tolerability of bosentan in idiopathic pulmonary fibrosis: an open label study. 2007 , 29, 713-9	59
440	Interstitial lung disease in systemic sclerosis. 2007 , 20, 223-8	4
439	Sildenafil improves walk distance in idiopathic pulmonary fibrosis. 2007 , 131, 897-899	181
438	Pulmonary Hypertension Related to Respiratory Disease. 2007 , 14, 286-295	1
437	Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. 2007 , 15, 76-86	52
436	The impact of pulmonary arterial hypertension on idiopathic pulmonary fibrosis. 2007 , 131, 641-3	17
435	Pulmonary Hypertension in Patients With Interstitial Lung Diseases. 2007 , 82, 342-350	62
434	Pulmonary artery pressure in lymphangiomyomatosis: an echocardiographic study. 2007 , 132, 1573-8	64
433	Use of sildenafil in heart transplant recipients with pulmonary hypertension may prevent right heart failure. 2007 , 39, 2850-2	28
432	Pathogenetic pathways and novel pharmacotherapeutic targets in idiopathic pulmonary fibrosis. 2007 , 20, 453-61	54

431	Effect of sildenafil on hypoxia-induced changes in pulmonary circulation and right ventricular function. 2007 , 159, 196-201		28
430	A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. 2007 , 153, 1037-47		179
429	Low-dose phosphodiesterase inhibition improves responsiveness to inhaled nitric oxide in isolated lungs from endotoxemic rats. 2007 , 138, 224-30		8
428	[Combined pulmonary fibrosis and emphysema]. 2007 , 36, 936-44		6
427	Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship. 2007 , 120, 306-13		52
426	Bosentan et fibrose pulmonaire. 2007 , 28, S230-S237		2
425	Pulmonary vascular disease in adults with congenital heart disease. 2007 , 115, 1039-50		292
424	Sildenafil Citrate Therapy in 22 Dogs with Pulmonary Hypertension. 2007 , 21, 1258-1264		88
423	Pulmonary hypertension associated with chronic respiratory disease. 2007 , 28, 219-32, x		36
422	Clinical perspective of hypoxia-mediated pulmonary hypertension. 2007 , 9, 711-21		31
421	Pulmonary hypertension in older adults. 2007 , 28, 717-33, vi		11
420	The nitric oxide/cGMP signaling pathway in pulmonary hypertension. 2007 , 28, 143-67, ix		66
419	[Evidence based respiratory medicine. 6th update workshop of SPLF March 30th, 2007. Interstitial lung diseases]. <i>Revue Des Maladies Respiratoires</i> , 2007 , 24, 1162-7	o	1
418	Combination therapy and new types of agents for pulmonary arterial hypertension. 2007 , 28, 169-85, ix		41
417	Pulmonary hypertension in patients with interstitial lung diseases. 2007 , 82, 342-50		58
416	Portopulmonary hypertension. 2007 , 28, 203-18, ix		51
415	[Oral sildenafil in neonatal medicine: "tested in adults also used in neonates"]. 2007 , 66, 167-76		7
414	Vardenafil and weaning from inhaled nitric oxide: effect on pulmonary hypertension in ARDS. 2007 , 35, 91-3		15

413	Pulmonary Hypertension. 2007,	
412	Sildenafil may facilitate weaning in mechanically ventilated COPD patients: a report of three cases. 2007, 35, 610-3	3
411	Traitement médical de l'hypertension artérielle pulmonaire. 2007, 56, S123-S136	
410	[Novel indications for phosphodiesterase type 5 inhibitors]. 2007, 102, 617-30	4
409	Pulmonale Hypertonie. 2007, 4, 283-302	2
408	[Diagnosis and therapy of chronic pulmonary hypertension]. 2007, 96, 301-30	22
407	Pulmonary hypertension: current diagnosis and treatment. 2007, 96, 527-41	53
406	Pulmonal artérielle Hypertonie. 2007, 2, 101-119	1
405	Quantitative analysis of sildenafil and desmethylsildenafil in human serum by liquid chromatography-mass spectrometry with minimal sample pretreatment. 2008, 876, 283-7	18
404	Treatment of pulmonary hypertension in children with chronic lung disease with newer oral therapies. 2008, 29, 1082-6	56
403	Interfield dysbalances in research input and output benchmarking: visualisation by density equalizing procedures. 2008, 7, 48	17
402	Pulmonary hypertension in interstitial lung disease. 2008, 62, 21-8	17
401	Vardenafil, but not sildenafil or tadalafil, has calcium-channel blocking activity in rabbit isolated pulmonary artery and human washed platelets. 2008, 154, 787-96	36
400	Combination therapy with prostacyclin and tadalafil for severe pulmonary arterial hypertension: a pilot study. 2008, 13, 916-8	29
399	Sildenafil: a review of its use in pulmonary arterial hypertension. 2008, 68, 383-97	50
398	Pulmonary Hypertension. 2008,	3
397	Pulmonary hypertension caused by sarcoidosis. 2008, 29, 549-63, x	48
396	Therapeutic advances in pulmonary arterial hypertension. 2008, 2, 249-65	30

395	Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?. 2008 , 27, 329-34	109
394	Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. 2008 , 129, 163-71	112
393	Sildenafil for pulmonary hypertension: dose-dependent improvement in exercise performance. 2008 , 21, 516-21	7
392	Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. 2008 , 21, 558-64	49
391	Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. 2008 , 21, 824-32	57
390	Vaso-active therapy can improve 6-min walk distance in patients with pulmonary hypertension and fibrotic interstitial lung disease. 2008 , 102, 1015-20	37
389	Pharmacotherapy in patients with idiopathic pulmonary fibrosis. 2008 , 9, 1909-25	5
388	Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. 2008 , 63 Suppl 5, v1-58	427
387	The right ventricle in sepsis. 2008 , 29, 661-76, ix	53
386	A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. 2009 , 30, 394-403	440
385	Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. 2008 , 32, 881-91	186
384	PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. 2008 , 294, L24-33	112
383	Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. 2008 , 76, 288-94	150
382	Uncertainties in the diagnosis and treatment of pulmonary arterial hypertension. 2008 , 118, 1195-201	78
381	Sildenafil in hypoxic pulmonary hypertension potentiates a compensatory up-regulation of NO-cGMP signaling. 2008 , 22, 30-40	36
380	Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. 2008 , 32, 198-209	101
379	Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. 2008 , 118, 2190-9	83
378	Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. 2008 , 31, 759-64	100

377	[Pulmonary arterial hypertension]. 2008 , 133, 1009-20	2
376	Sildenafil acutely reverses the hypoxic pulmonary vasoconstriction response of the newborn pig. 2008 , 64, 251-5	7
375	Pulmonary hypertension in interstitial lung disease. 2008 , 31, 1357-67	189
374	Pulmonary hypertension in interstitial lung disease. 2008 , 14, 462-9	17
373	Guidelines for the diagnosis and treatment of pulmonary hypertension. 2009 , 34, 1219-63	919
372	Vardenafil treatment for patients with pulmonary arterial hypertension: a multicentre, open-label study. 2009 , 95, 1531-6	32
371	Acute right ventricular failure from pathophysiology to new treatments. 2009 , 261-272	1
370	Expression and activity of phosphodiesterase isoforms during epithelial mesenchymal transition: the role of phosphodiesterase 4. 2009 , 20, 4751-65	73
369	Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. 2009 , 135, 1455-1461	122
368	PDE5 inhibitors in non-urolological conditions. 2009 , 15, 3521-39	24
367	Pulmonary hypertension in chronic obstructive pulmonary disease and interstitial lung diseases. 2009 , 30, 458-70	72
366	Pulmonary arterial hypertension in human immunodeficiency virus infection. 2009 , 121, 56-67	7
365	[Pulmonary hypertension in COPD and interstitial lung diseases]. 2009 , 134 Suppl 5, S164-6	2
364	Pulmonary hypertension in COPD: a review and consideration of the role of arterial vasodilators. 2009 , 6, 137-44	32
363	Improvement of pulmonary microcirculation after lung transplantation using phosphodiesterase-5 inhibitor modified preservation solution. 2009 , 35, 801-6	6
362	The ENDOTRIAL study: a spontaneous, open-label, randomized, multicenter, crossover study on the efficacy of sildenafil, tadalafil, and vardenafil in the treatment of erectile dysfunction. 2009 , 6, 2547-60	41
361	Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme. 2009 , 21, 1768-74	18
360	Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. 2009 , 60, 569-77	190

359	[Interstitial lung diseases and pulmonary hypertension]. 2009 , 50, 1072, 1074-6, 1078-9	0
358	Role of oral sildenafil in the treatment of right ventricular dysfunction after heart transplantation. 2009 , 41, 1353-6	27
357	Metered dose inhaler delivery of treprostinil for the treatment of pulmonary hypertension. 2009 , 22, 50-6	36
356	Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition. 2009 , 28, 676-82	40
355	Treprostinil to reverse pulmonary hypertension associated with idiopathic pulmonary fibrosis as a bridge to single-lung transplantation. 2009 , 28, 964-7	8
354	Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). 2009 , 30, 2493-537	2531
353	Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. 2009 , 54, S85-S96	284
352	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. 2009 , 62, 1464.e1-1464.e58	1
351	Effects and mechanisms of action of sildenafil citrate in human chorionic arteries. 2009 , 7, 34	26
350	cGMP: Generators, Effectors and Therapeutic Implications. <i>Handbook of Experimental Pharmacology</i> , 2009 ,	3.2 13
349	Soluble guanylate cyclase stimulation: an emerging option in pulmonary hypertension therapy. 2009 , 18, 35-41	38
348	First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. 2009 , 33, 785-92	186
347	Treatment of idiopathic interstitial pneumonias. 2009 , 3, 81-91	
346	Guía de práctica clínica para el diagnóstico y tratamiento de la hipertensión pulmonar. 2009 , 62, 1464.e1-1464.e58	3
345	Pulmonary Hypertension in Interstitial Lung Disease Diagnosis and Management. 2009 , 16, 252-257	
344	Schistosomiasis-associated pulmonary hypertension: pulmonary vascular disease: the global perspective. 2010 , 137, 20S-29S	84
343	Sildenafil attenuates pulmonary arterial pressure but does not improve oxygenation during ARDS. 2010 , 36, 758-64	34
342	Noninvasive assessment of acute cardiopulmonary effects of an oral single dose of sildenafil in patients with idiopathic pulmonary hypertension. 2010 , 25, 313-8	7

341	Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. 2010 , 188, 115-23	59
340	Oral sildenafil: potential role in heart transplantation. Review of the literature and personal experience. 2010 , 55, 291-5	11
339	Secondary pulmonary hypertension. 2010 , 3, 1-9	3
338	Phosphodiesterase inhibitors in the management of autoimmune disease. 2010 , 9, 511-5	24
337	[PDE5 inhibitors in the treatment of pulmonary hypertension]. 2010 , 39, 391-6	1
336	The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. 2010 , 15, 1226-32	29
335	Dramatic response of a patient with pregnancy induced idiopathic pulmonary arterial hypertension to sildenafil treatment. 2010 , 36, 414-7	7
334	Update on the clinical utility of sildenafil in the treatment of pulmonary arterial hypertension. 2010 , 4, 61-70	28
333	Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. 2010 , 31, 1124-31	137
332	Management of dyspnea in interstitial lung disease. 2010 , 4, 69-75	13
331	Penile involvement in Systemic Sclerosis: New Diagnostic and Therapeutic Aspects. 2010 , 2010, 708067	4
330	Clinical use of sildenafil in pulmonary artery hypertension. 2010 , 4, 13-9	11
329	Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. 2010 , 36, 792-9	186
328	[Pulmonary hypertension related to pulmonary diseases or hypoxia and its treatment]. 2010 , 10 Suppl 2, 47-55	
327	Pulmonary arterial hypertension and lung transplantation. 2010 , 31, 147-60	12
326	A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. 2010 , 363, 620-8	421
325	Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. 2010 , 181, 270-8	210
324	Pulmonary vascular and right ventricular dysfunction in adult critical care: current and emerging options for management: a systematic literature review. 2010 , 14, R169	221

323	Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. 2010 , 79, 377-82	68
322	Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension. 2010 , 55, 1456-62	25
321	Current therapeutic approaches to pulmonary arterial hypertension. 2010 , 63, 708-24	2
320	Pulmonary hypertension in dogs: diagnosis and therapy. 2010 , 40, 623-41	92
319	Pulmonary hypertension in lung diseases: survey of beliefs and practice patterns. 2010 , 104, 741-8	12
318	Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. 2010 , 159, 245-57	85
317	Clinical efficacy of sildenafil in treatment of pulmonary arterial hypertension in dogs. 2010 , 24, 850-4	56
316	The effect of sildenafil citrate administration on selected physiological parameters of exercising Thoroughbred horses. 2010 , 42, 606-12	6
315	Current and future therapy for pulmonary hypertension in patients with right and left heart failure. 2010 , 8, 241-50	2
314	Impact of sildenafil therapy on pulmonary arterial hypertension in adults with congenital heart disease. 2010 , 28, 350-5	16
313	Estrategias terapéuticas actuales en la hipertensión arterial pulmonar. 2010 , 63, 708-724	15
312	Pulmonary hypertension associated with parenchymal lung disease. 2010 , 26, 21B-23B	1
311	Riociguat for pulmonary hypertension. 2010 , 6, 155-66	24
310	An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. 2011 , 183, 788-824	4665
309	Comprehensive Cardiovascular Medicine in the Primary Care Setting. 2011 ,	
308	Riociguat for the treatment of pulmonary hypertension. 2011 , 20, 567-76	69
307	Current therapeutics and practical management strategies for pulmonary arterial hypertension. 2011 , 162, 201-13	37
306	Acute effect of sildenafil on hypoxemic patients (excluding those with Eisenmenger syndrome) with incurable congenital heart disease and disturbed pulmonary vasculature in the mid-term follow-up. 2011 , 146, 273-4	2

305	[Pulmonary hypertension in interstitial lung diseases: diagnostic and therapeutic approach in 2011?]. 2011 , 40 Suppl 1, 1S39-45		0
304	Tadalafil for the treatment of pulmonary arterial hypertension. 2011 , 5, 315-28		7
303	Idiopathic pulmonary fibrosis. <i>Lancet, The</i> , 2011 , 378, 1949-61	40	1196
302	L'ipertensione polmonare e lo scompenso cardiaco destro nella malattia renale cronica: curiosità da cardionefrologo?. 2011 , 23, 84-90		
301	Acute effect of sildenafil is maintained in pulmonary arterial hypertension patients chronically treated with bosentan. 2011 , 52, 233-9		13
300	Therapeutic strategies in pulmonary hypertension. 2011 , 2, 21		10
299	Phosphodiesterase-5 inhibition mimics intermittent reoxygenation and improves cardioprotection in the hypoxic myocardium. 2011 , 6, e27910		20
298	Clinical trials in idiopathic pulmonary fibrosis: update and perspectives. 2011 , 1, 1669-1680		
297	Pulmonary Hypertension in Interstitial Lung Disease. 2011 , 18, 222-229		
296	Clinical trials using vasodilators in pulmonary arterial hypertension: where do we go from here?. 2011 , 6, 228-34		5
295	Effects of inhaled nitric oxide at rest and during exercise in idiopathic pulmonary fibrosis. 2011 , 110, 638-45		32
294	Two cases of stem cell therapy for pulmonary hypertension: A clinical report. 2011 , 4, 70-74		1
293	Metal ion stimulators of PDE5 cause similar conformational changes in the enzyme as does cGMP or sildenafil. 2011 , 23, 778-84		4
292	Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding. 2011 , 23, 1578-83		5
291	Sildenafil does not improve steady state cardiovascular hemodynamics, peak power, or 15-km time trial cycling performance at simulated moderate or high altitudes in men and women. 2011 , 111, 3031-40		18
290	Pulmonale Hypertonie bei chronischen Lungenerkrankungen. 2011 , 8, 113-127		
289	Idiopathic pulmonary fibrosis: treatment update. 2011 , 28, 986-99		20
288	Potential for phosphodiesterase inhibitors in the management of autoimmune diseases. 2011 , 72, 772-778		1

287	Systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. 2011 , 63, 2456-64	87
286	Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. 2011 , 45, 1-15	153
285	Clinical year in review I: interstitial lung disease, occupational and environmental lung disease, education of residents and fellows, and pediatrics. 2011 , 8, 389-97	2
284	Pulmonary hypertension, nitric oxide and nitric oxide-releasing compounds. 2011 , 5, 163-71	15
283	Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. 2011 , 82, 294-304	52
282	Lung transplantation for pulmonary hypertension. 2011 , 1, 182-91	31
281	Pulmonary hypertension secondary to interstitial lung disease. 2011 , 5, 179-89	16
280	Pathophysiology of pulmonary hypertension in acute lung injury. 2012 , 302, L803-15	78
279	Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. 2012 , 14, 82-90	87
278	Pulmonary Hypertension Complicating Interstitial and Granulomatous Lung Diseases. 2012 , 178-198	1
277	Aging and Lung Disease. 2012 ,	
276	Pulmonary hypertension in parenchymal lung disease. 2012 , 2012, 684781	4
275	Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications. 2012 , 1, 233-242	7
274	Right ventricular dysfunction in chronic lung disease. 2012 , 30, 243-56	33
273	Orientaes para o diagnstico e tratamento da hipertenso pulmonar. 2012 , 31, 71-115	
272	Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. 2012 , 9, 268-75	68
271	Les inhibiteurs de la phosphodiesterase 5 dans les maladies vasculaires systmiques. 2012 , 79, 187-190	
270	17Estradiol attenuates hypoxic pulmonary hypertension via estrogen receptor-mediated effects. 2012 , 185, 965-80	119

269	Hypoxic pulmonary vasoconstriction. 2012 , 92, 367-520	444
268	Pulmonary hypertension complicating sarcoidosis. 2012 , 41, e303-16	24
267	Benzenesulfonamide attenuates monocrotaline-induced pulmonary arterial hypertension in a rat model. 2012 , 690, 176-82	9
266	Acute haemodynamic response in relation to plasma vardenafil concentrations in patients with pulmonary hypertension. 2012 , 74, 990-8	4
265	Genistein, a soy phytoestrogen, reverses severe pulmonary hypertension and prevents right heart failure in rats. 2012 , 60, 425-30	62
264	Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: case report and review of the literature. 2012 , 41, 512-7	12
263	World Health Organization Group III pulmonary hypertension. 2012 , 55, 119-27	21
262	Why all pulmonary hypertensive patients need a heart catheter study?. 2012 , 34, 123-127	
261	Pulmonary hypertension in parenchymal lung disease. 2012 , 8, 461-74	7
260	Recent advances and future perspectives in therapeutic strategies for pulmonary arterial hypertension. 2012 , 60, 344-9	21
259	Cyclic nucleotide phosphodiesterase (PDE) isozymes as targets of the intracellular signalling network: benefits of PDE inhibitors in various diseases and perspectives for future therapeutic developments. 2012 , 165, 1288-305	224
258	[Disproportionate pulmonary arterial hypertension and lung respiratory diseases: distinctive clinical, hemodynamic and prognosis of patients versus primary pulmonary arterial hypertension]. 2012 , 61, 1-7	
257	Phosphodiesterase 5 inhibitors in vascular systemic disorders. 2012 , 79, 338-40	2
256	How to evaluate the efficacy of the phosphodiesterase type 5 inhibitors. 2012 , 9, 26-33	24
255	Effects of epoprostenol and sildenafil on right ventricular function in hypoxic volunteers: a tissue Doppler imaging study. 2012 , 112, 1285-94	15
254	High inter-individual variability of vardenafil pharmacokinetics in patients with pulmonary hypertension. 2013 , 69, 197-207	6
253	Four cases with group 3 out-of-proportion pulmonary hypertension with a favorable response to vasodilators. 2013 , 9, 4-7	4
252	Pharmacotherapy of Pulmonary Hypertension. <i>Handbook of Experimental Pharmacology</i> , 2013 ,	3.2 2

251	Pulmonary hypertension in chronic lung diseases. 2013 , 62, D109-16	390
250	[French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Société de Pneumologie de Langue Française]. <i>Revue Des Maladies Respiratoires</i> , 2013 , 30, 879-902	26
249	Pulmonary arterial hypertension. 2013 , 8, 97	168
248	Die Therapie der idiopathischen pulmonalen Fibrose. 2013 , 10, 105-111	1
247	Pediatric pulmonary arterial hypertension. 2013 , 15, 606-13	4
246	Pulmonary hypertension in chronic obstructive and interstitial lung diseases. 2013 , 168, 1795-804	22
245	Pulmonary hypertension due to lung disease and/or hypoxia. 2013 , 34, 695-705	26
244	56-year-old man with pulmonary hypertension. 2013 , 32, 111-4	
243	Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics. 2013 , 9, 335-49	26
242	Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. 2013 , 143, 1699-1708	149
241	Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. 2013 , 34, 811-24	4
240	[German guideline for diagnosis and management of idiopathic pulmonary fibrosis]. 2013 , 67, 81-111	52
239	Preoperative pulmonary artery pressure and mortality after lung transplantation. 2013 , 21, 326-30	1
238	Treatment of pulmonary hypertension in interstitial lung disease: do not throw out the baby with the bath water. 2013 , 41, 781-3	10
237	Pulmonary hypertension and idiopathic pulmonary fibrosis: a dastardly duo. 2013 , 346, 221-5	27
236	Endocannabinoid anandamide mediates hypoxic pulmonary vasoconstriction. 2013 , 110, 18710-5	42
235	Pulmonary hypertension in chronic interstitial lung diseases. 2013 , 22, 292-301	55
234	Idiopathic pulmonary fibrosis: recent trials and current drug therapy. 2013 , 86, 353-63	26

233	Treatment of pulmonary hypertension caused by left heart failure with pulmonary arterial hypertension-specific therapies: lessons from the right and LEPHT. 2013 , 128, 475-6	5
232	Oral sildenafil as a rescue therapy in presumed acute pulmonary hypertensive crisis. 2013 , 131, e626-8	4
231	Effects of simvastatin on pulmonary fibrosis, pulmonary hypertension and exercise capacity in bleomycin-treated rats. 2013 , 208, 191-201	15
230	Current challenges in pediatric pulmonary hypertension. 2013 , 34, 627-44	18
229	Pulmonary heart disease: The heart-lung interaction and its impact on patient phenotypes. 2013 , 3, 5-19	37
228	Pulmonary hypertension complicating interstitial lung disease and COPD. 2013 , 34, 600-19	16
227	Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. 2013 , 41, 853-60	106
226	Pulmonary Hypertension and Right Heart Failure in Chronic Kidney Disease: New Challenge for 21st-Century Cardioneurologists. 2013 , 3, 96-103	23
225	Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. 2013 , 23, 1211-1220	16
224	Pulmonary Hypertension in Chronic Lung Diseases and/or Hypoxia. 2013 ,	1
223	The diagnosis and treatment of idiopathic pulmonary fibrosis. 2013 , 110, 875-81	20
222	Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?. 2014 , 8, 875-85	19
221	Pulmonary Hypertension Associated with Respiratory Diseases. 2014 , 1-25	
220	Effect of preoperative oral sildenafil on severe pulmonary artery hypertension in patients undergoing mitral valve replacement. 2014 , 46, 281-5	10
219	Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. 2014 , 19, 700-6	27
218	Riociguat for pulmonary hypertension. 2014 , 7, 259-70	6
217	Nonpulmonary influences on gas exchange. 2014 , 4, 1455-94	7
216	Pulmonary hypertension complicating pulmonary fibrosis: bad and ugly, but good to treat?. 2014 , 69, 107-8	4

215	"Pulmonary hypertension in Saudi Arabia: A single center experience," which was published in the previous issue of Annals of Thoracic Medicine. 2014 , 9, 49	
214	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. 2014 , 2014, 257-90	10
213	The endothelial ADMA/NO pathway in hypoxia-related chronic respiratory diseases. 2014 , 2014, 501612	23
212	Effect of sildenafil in the management of preoperative pulmonary hypertension Available online 22 June 2013 View all notes Peer review under responsibility of Alexandria University Faculty of Medicine. View all notes. 2014 , 50, 13-16	0
211	Combination of sildenafil and bosentan for pulmonary hypertension in a human ex vivo model. 2014 , 28, 45-51	4
210	Drug treatment of pulmonary hypertension in children. 2014 , 16, 43-65	32
209	Idiopathic Pulmonary Fibrosis. 2014 ,	1
208	Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease. 2014 , 66, 1900-8	34
207	Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. 2014 , 69, 123-9	47
206	[Pulmonary hypertension in chronic respiratory diseases]. 2014 , 43, 945-56	1
205	Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. 2014 , 190, 208-17	116
204	Outcome of patients with severe PH due to lung disease with and without targeted therapy. 2014 , 32, 202-8	19
203	Core Knowledge in Critical Care Medicine. 2014 ,	
202	Comprehensive Approach to Adult Congenital Heart Disease. 2014 ,	3
201	An official American Thoracic Society/American College of Chest Physicians policy statement: the Choosing Wisely top five list in adult pulmonary medicine. 2014 , 145, 1383-1391	50
200	Stepwise Approach Using Combined Management in Patients with Congenital Heart Disease and Borderline Pulmonary Vascular Disease. 2015 , 45, 408-15	
199	Propylthiouracil Attenuates Experimental Pulmonary Hypertension via Suppression of Pen-2, a Key Component of Gamma-Secretase. 2015 , 10, e0137426	9
198	Efficacy of pulmonary vasodilator therapy in patients with functionally single ventricle. 2015 , 56 Suppl, S26-30	9

197	Therapy of heavy menstrual bleeding in Korea: Subanalysis and results from a multinational clinical trial in the Asian region investigating the levonorgestrel-releasing intrauterine system versus conventional therapy. 2015 , 58, 162-70	2
196	Diagnosis and Management of Pulmonary Hypertension. <i>Respiratory Medicine</i> , 2015 ,	0.2
195	Pediatric Pulmonary Hypertension: Guidelines From the American Heart Association and American Thoracic Society. 2015 , 132, 2037-99	624
194	Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. 2015 , 47, 100-5	22
193	Sildenafil versus nitric oxide for acute vasodilator testing in pulmonary arterial hypertension. 2015 , 5, 305-12	13
192	Avances en el diseo de farmacos asistido por computadora. 2015 , 26, 180-186	3
191	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. 2015 , 192, e3-19	1122
190	Management of Pulmonary Hypertension in Patients with Chronic Lung Disease. 2015 , 17, 62	10
189	Current Treatment Strategies, Guidelines and New Therapies. 2015 , 81-145	
188	Treatment of Pulmonary Hypertension. 2015 ,	1
187	Interventional Cardiology in the Elderly. 2015 ,	
186	A case of diffuse panbronchiolitis, associated with severe pulmonary hypertension, managed with bilateral lung transplantation from a brain-dead donor. 2015 , 53, 242-6	3
185	Idiopathic pulmonary fibrosis with complication of severe respiratory failure, right heart failure, and steroid induced diabetes  qualification for lung transplantation as a matter of urgency. 2016 , 3, 196-198	
184	Pulmonary Hypertension Due to Common Respiratory Conditions: Classification, Evaluation and Management Strategies. 2016 , 5,	10
183	Severe Pulmonary Arteriopathy Is Associated with Persistent Hypoxemia after Pulmonary Endarterectomy in Chronic Thromboembolic Pulmonary Hypertension. 2016 , 11, e0161827	8
182	The effects of pulmonary vasodilating agents on right ventricular parameters in severe group 3 pulmonary hypertension: a pilot study. 2016 , 6, 524-531	6
181	Idiopathic Pulmonary Fibrosis: Epidemiology, Clinical Features, Prognosis, and Management. 2016 , 37, 331-57	19
180	Drug Repurposing for Epigenetic Targets Guided by Computational Methods. 2016 , 327-357	14

179	Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments. 2016 , 34, 413-33		38
178	Under-recognised co-morbidities in idiopathic pulmonary fibrosis: A review. 2016 , 21, 995-1004		6
177	[Pulmonary hypertension due to chronic lung disease: Recommendations of the Cologne Consensus Conference 2016]. 2016 , 141, S57-S61		6
176	Effects of extrathoracic mechanical ventilation on pulmonary hypertension secondary to lung disease. 2016 , 30, 663-70		3
175	Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science. 2016 , 47, 1615-7		7
174	Is there a role for sildenafil in the management of paraquat-induced lung fibrosis?. 2016 , 67, 167-8		2
173	Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: an ex vivo/in vitro study. 2016 , 47, 1737-49		23
172	Hypoxic pulmonary hypertension in chronic lung diseases: novel vasoconstrictor pathways. 2016 , 4, 225-36		40
171	Pulmonary Hypertension Due to Lung Disease. 2016 , 1050-1065.e5		0
170	Superior vasodilation of human pulmonary vessels by vardenafil compared with tadalafil and sildenafil: additive effects of bosentan. 2017 , 25, 254-259		7
169	Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. 2017 , 50,		61
168	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2017 update. Full-length version. <i>Revue Des Maladies Respiratoires</i> , 2017 , 34, 900-968	o	28
167	[French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. 2017 update. Full-length update]. <i>Revue Des Maladies Respiratoires</i> , 2017 ,	o	6
166	Pulmonary Hypertension in Idiopathic Interstitial Pneumonias. 2017 , 103-128		
165	Pulmonary Hypertension and Interstitial Lung Disease. 2017 ,		
164	Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. 2017 , 151, 204-214		12
163	Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. 2017 , 5, 72-84		97
162	Pharmacodynamics, pharmacokinetics and clinical efficacy of phosphodiesterase-5 inhibitors. 2017 , 13, 183-192		19

161	The principal pathways involved in the in vivo modulation of hypoxic pulmonary vasoconstriction, pulmonary arterial remodelling and pulmonary hypertension. 2017 , 219, 728-756	49
160	Erectile Dysfunction Medications and Treatment for Cardiometabolic Risk Factors: A Pharmacoepidemiologic Study. 2017 , 14, 1597-1605	4
159	Complex Pathophysiology of Pulmonary Hypertension Associated with Systemic Sclerosis: Potential Unfavorable Effects of Vasodilators. 2017 , 2, 92-99	5
158	Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives. 2017 , 2017, 1430350	39
157	Diagnostic criteria, severity classification and guidelines of systemic sclerosis. 2018 , 45, 633-691	16
156	Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design. 2018 , 138, 13-20	22
155	Hypoxia Upregulates Estrogen Receptor α In Pulmonary Artery Endothelial Cells in a HIF-1 β -Dependent Manner. 2018 , 59, 114-126	21
154	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. 2018 , 198, 166-174	14
153	Perioperative Management of Pulmonary Hypertension and Right Ventricular Failure During Noncardiac Surgery. 2018 , 36, 201-230	2
152	Long term follow-up of multidrug resistant tuberculosis in a pubertal child. 2018 , 58, 198-204	
151	Effect of combinations of caffeine and caffeic acid on key enzymes linked to hypertension (in vitro). 2018 , 18, 247-255	6
150	Pulmonary Hypertension Related to Chronic Obstructive Pulmonary Disease and Diffuse Parenchymal Lung Disease: A Focus on Right Ventricular (Dys)Function. 2018 , 14, 403-411	2
149	Emerging therapeutics in pulmonary hypertension. 2018 , 314, L769-L781	17
148	EP4 Agonist L-902,688 Suppresses EndMT and Attenuates Right Ventricular Cardiac Fibrosis in Experimental Pulmonary Arterial Hypertension. 2018 , 19,	19
147	The Rationale for Repurposing Sildenafil for Lung Cancer Treatment. 2018 , 18, 367-374	12
146	Pulmonary hypertension due to lung diseases: Updated recommendations from the Cologne Consensus Conference 2018. 2018 , 272S, 63-68	21
145	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). 2019 , 200, 1505-1512	30
144	Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis. 2019 , 8, e013310	4

143	Circular RNA hsa_circ_0016070 Is Associated with Pulmonary Arterial Hypertension by Promoting PASMC Proliferation. 2019 , 18, 275-284	36
142	Adjunctive therapies in idiopathic pulmonary fibrosis-where do we stand?. 2019 , 11, 357-360	
141	Improvement of pulmonary arterial hypertension, inflammatory response, and epithelium injury by dual activation of cAMP/cGMP pathway in a rat model of monocrotaline-induced pulmonary hypertension. 2019 , 83, 1000-1010	5
140	p38 mitogen activated protein kinase mediates cardiac Na/H exchanger inhibition induced by Sildenafil. 2019 , 849, 96-105	2
139	Phosphodiesterase 5 inhibitors for pulmonary hypertension. 2019 , 1, CD012621	32
138	Pulmonary hypertension due to interstitial lung disease. 2019 , 25, 459-467	12
137	Lung Transplantation for Interstitial Lung Disease. 2019 , 131-149	
136	Imatinib for right heart failure in COPD. 2019 , 9, 2045894018816974	1
135	Pulmonary hypertension in chronic lung disease and hypoxia. 2019 , 53,	231
134	Idiopathic interstitial pneumonias. 2020 , 29-140	0
133	A 50-Year-Old Woman With Limited Scleroderma Presenting With Shortness of Breath. 2020 , 158, e37-e40	1
132	Trends in Systemic Sclerosis Mortality Over Forty-Eight Years, 1968-2015: A US Population-Based Study. 2021 , 73, 1502-1510	5
131	Clinical trials in group 3 pulmonary hypertension. 2020 , 26, 391-396	3
130	NADPH oxidases: Pathophysiology and therapeutic potential in age-associated pulmonary fibrosis. 2020 , 33, 101541	13
129	The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment. 2020 , 158, 1651-1664	15
128	Cardiac Considerations in Chronic Lung Disease. <i>Respiratory Medicine</i> , 2020 ,	0.2 0
127	Rapid transition from oral selexipag to parenteral treprostinil in a patient with mixed-etiology pulmonary hypertension. 2020 , 77, 1208-1212	
126	Efficacy and safety of Sildenafil treatment in pulmonary hypertension caused by chronic obstructive pulmonary disease: A meta-analysis. 2020 , 257, 118001	7

125	Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra. 2021 , 178, 172-186	7
124	Secondary pulmonary hypertension due to pulmonary Langerhans cell histiocytosis accompanied with panhypopituitarism. 2021 , 9, e00697	
123	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. 2021 , 9, 85-95	33
122	Pulmonary Hypertension Associated With Respiratory Diseases - Which Patients Should Be Treated With Pulmonary Arterial Hypertension-Targeted Therapies?. 2021 , 85, 343-344	
121	Pyrazole Carboxylic Acid and Derivatives: Synthesis and Biological Applications. 2021 , 18, 93-109	1
120	Group 3 Pulmonary Hypertension: A Review of Diagnostics and Clinical Trials. 2021 , 42, 59-70	3
119	Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction. 2021 , 13, 1466-1475	
118	Significance of autoimmune disease in severe pulmonary hypertension complicating extensive pulmonary fibrosis: a prospective cohort study. 2021 , 11, 20458940211011329	3
117	Repurposing of sildenafil as antitumour; induction of cyclic guanosine monophosphate/protein kinase G pathway, caspase-dependent apoptosis and pivotal reduction of Nuclear factor kappa light chain enhancer of activated B cells in lung cancer. 2021 , 73, 1080-1091	1
116	Pulmonary Hypertension. 2021 , 174, ITC49-ITC64	7
115	Adherence, Persistence, and Effectiveness in Real Life. Multicenter Long-Term Study on the Use of Pirfenidone and Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis. 2021 , 8971900211008625	0
114	Sildenafil in endotoxin-induced pulmonary hypertension: an experimental study. 2021 ,	
113	Comparison of Three Different Aqueous Microenvironments for Enhancing Oral Bioavailability of Sildenafil: Solid Self-Nanoemulsifying Drug Delivery System, Amorphous Microspheres and Crystalline Microspheres. 2021 , 16, 5797-5810	4
112	Assessing pulmonary hypertension severity in lung disease is a key step to improving outcomes: embrace resistance and don't be pressurised to go with the flow. 2021 , 58,	1
111	Impairment of hypoxic pulmonary vasoconstriction in acute respiratory distress syndrome. 2021 , 30,	6
110	Group 3 PH: Clinical Features and Treatment. 2022 , 678-690	
109	Phase three clinical trials in idiopathic pulmonary fibrosis. 2021 , 9, 1-11	0
108	The NO - K+ channel axis in pulmonary arterial hypertension. Activation by experimental oral therapies. 2003 , 543, 293-322	16

107	Review of the MIGET Literature. 2017 , 145-233		2
106	Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. 2009 , 177-194		1
105	Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations. <i>Respiratory Medicine</i> , 2020 , 79-96	0.2	1
104	Modulating cGMP to treat lung diseases. <i>Handbook of Experimental Pharmacology</i> , 2009 , 469-83	3.2	8
103	Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction. <i>Handbook of Experimental Pharmacology</i> , 2013 , 218, 315-49	3.2	10
102	Intravenous epoprostenol treatment of patients with connective tissue disease and pulmonary arterial hypertension at a single center. 2013 , 23, 1211-20		7
101	Management of the Infant with Congenital Diaphragmatic Hernia. 2012 , 381-406		1
100	New Developments in the Pathogenesis and Management of Neonatal Pulmonary Hypertension. 2008 , 241-299		4
99	Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan. 2006 , 99, 880-3		14
98	Reversal of experimental pulmonary hypertension by PDGF inhibition. 2005 , 115, 2811-21		764
97	Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching. 2018 , 13, e0191239		10
96	Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis. Federal Guidelines. <i>Pulmonologiya</i> , 2016 , 26, 399-419	0.8	26
95	Sildenafil in the treatment of pulmonary hypertension. 2006 , 2, 411-22		88
94	Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. <i>Advances in Pulmonary Hypertension</i> , 2013 , 12, 127-134	0.5	1
93	Evaluating Operability in Adults with Congenital Heart Disease and the Role of Pretreatment with Targeted Pulmonary Arterial Hypertension Therapy. <i>Advances in Pulmonary Hypertension</i> , 2007 , 6, 126-135	0.5	2
92	Hypoxic Pulmonary Vasoconstriction in Humans: Tale or Myth. 2017 , 11, 1-13		14
91	[Exacerbation of idiopathic pulmonary fibrosis]. 2020 , 92, 73-77		0
90	Tadalafil: A Comprehensive Update. 2004 , 2, 225-246		1

89	The Clinical Efficacy of Pulmonary Hypertension-Specific Agents in Idiopathic Pulmonary Fibrosis: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. 2020 , 35, e48	4
88	Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease. 2007 , 22, 37-9	4
87	Connective Tissue Disease, Interstitial Lung Disease, and Pulmonary Hypertension (CTD PH-ILD): A Distinct Entity and Potential Opportunity. <i>Advances in Pulmonary Hypertension</i> , 2021 , 20, 109-118	0.5
86	Management of PH-ILD: Past, Present, and Future. <i>Advances in Pulmonary Hypertension</i> , 2021 , 20, 119-122	0.5
85	NO pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. 2004 , 163-168	
84	Sildenafil, pharmacology of a highly selective PDE5 inhibitor. 2004 , 15-33	2
83	Treatment of Pulmonary Hypertension Related to Disorders of Hypoxia. <i>Advances in Pulmonary Hypertension</i> , 2005 , 4, 14-22	0.5
82	Pulmonary Hypertension in Children. 2006 , 274-287	
81	Erectile Dysfunction and the Heart. 2006 , 367-373	
80	Pulmonary Arterial Hypertension. 2006 , 543-548	
79	High Altitude Pulmonary Edema. 2006 , 288-304	
78	Role of PDE5 in Migraine. 2006 ,	
77	Pulmonary Arterial Hypertension. 2007 , 2203-2246	
76	Lungengefäßkrankungen. 2008 , 433-528	
75	Cardiovascular Pharmacological Agents. 2008 , 17-60	
74	Nitric Oxide. 2009 , 1-6	
73	Idiopathic Pulmonary Fibrosis and Associated Pulmonary Hypertension: Genetics, Pathobiology, Diagnosis, and Management. 2009 , 51-69	
72	Effect of Sildenafil on Pulmonary Hypertension after a Case of Residual Shunt of Ventricular Septal Defect. <i>Japanese Journal of Cardiovascular Surgery</i> , 2009 , 38, 252-258	0.1

- 71 Chronic Pulmonary Hypertension. **2009**, 483-505
- 70 Lungen- und Atemwegserkrankungen. **2009**, 275-376
- 69 Acute right heart failure. **2009**, 89-111
- 68 Sarcoidosis. **2009**, 213-242
- 67 Current approach to diagnosis and therapy of pulmonary hypertension in patients with chronic obstructive pulmonary disease. *Pulmonologiya*, **2009**, 90-101 0.8 2
- 66 Pulmonary Hypertension. **2009**, 893-918
- 65 Diagnosis and Management of Pulmonary Hypertension Associated With Pulmonary Fibrosis. *Advances in Pulmonary Hypertension*, **2009**, 8, 141-147 0.5
- 64 The role of the cath lab in patients with advanced heart failure and cardiac transplantation. **2009**, 237-240
- 63 Surgical outcome of severe pulmonary arterial hypertension secondary to left-to-right shunt lesions. *Korean Journal of Pediatrics*, **2010**, 53, 195 2.4
- 62 Nitric Oxide and Inhaled Pulmonary Vasodilators. **2010**, 941-955
- 61 Cor Pulmonale. **2010**, 1326-1355
- 60 Role of sildenafil in the treatment of pulmonary hypertension. *Journal of the Japanese Society of Intensive Care Medicine*, **2010**, 17, 462-464 0
- 59 Pulmonary Hypertension and Cor Pulmonale. **2011**, 353-371
- 58 Pulmonary Hypertension Associated with Interstitial Lung Disease. **2011**, 1197-1210
- 57 Phosphodiesterase Inhibitors in the Treatment of Pulmonary Hypertension. **2011**, 1477-1485
- 56 Immunologische Herzerkrankungen. **2011**, 363-372
- 55 Inhaled nitric oxide and nitric oxide donors. **2011**, 326-334
- 54 Pulmonary hypertension due to chronic hypoxic lung disease. **2011**, 457-471

53 ????????????? : ?????????????(6.????????,75????????). *Journal of JCS Cardiologists*, **2011**, 19, 271-277 0.1

52 Pulmonary Hypertension in Older Patients. **2012**, 111-131

51 Pulmonary Hypertension in Interstitial Lung Disease. **2012**, 121-135

50 Primäre pulmonale Hypertonie. **2012**, 619-624

49 Acute right ventricular failure from pathophysiology to new treatments. **2012**, 131-142

48 A Case of Adenocarcinoma of the Lung Complicated with Chronic Thromboembolic Pulmonary Hypertension That Underwent Upper Pulmonary Lobectomy. *Japanese Journal of Lung Cancer*, **2012**, 52, 1023-1029 0.1

47 Serganų portopulmonine hipertenzija diagnostikos, medikamentinio gydymo ir kepenų transplantacijos ypatumai. *Health Sciences*, **2012**, 22, 118-124 0 1

46 A Case of Interstitial Pneumonia whose Symptoms were Exacerbated by Treatment of Pulmonary Arterial Hypertension. *Kitakanto Medical Journal*, **2013**, 63, 159-164 0

45 Recognizing and Treating Comorbidities of IPF. **2014**, 313-336

44 Right Heart Failure. **2014**, 311-329

43 Pharmacological Treatment of Idiopathic Pulmonary Fibrosis. **2014**, 297-311

42 Pulmonary Hypertension Associated with Congenital Heart Disease, Eisenmenger Syndrome. **2014**, 117-124

41 Oxygen Supplementation, Delivery, and Physiologic Effects. **2015**, 123-134

40 Hypoxic Pulmonary Hypertension. *Respiratory Medicine*, **2015**, 67-92 0.2

39 Pulmonary Hypertension in the Elderly: Impact of Age on Diagnosis and Therapy Options. **2015**, 109-133

38 The Real World of Medical Treatment of Pulmonary Arterial Hypertension—Small Evidence, but Heavy Cornerstone—*Nihon Shoni Junkanki Gakkai Zasshi = Pediatric Cardiology and Cardiac Surgery*, **2015**, 31, 157-183 0

37 Pulmonary Hypertension Associated with Respiratory Disease. **2015**, 4211-4231

36 Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension. **2016**, 29-61

35	Non-Group 1 Pulmonary Hypertension Associated With Systemic Sclerosis: An Under-studied Patient Population. <i>Advances in Pulmonary Hypertension</i> , 2017 , 16, 68-75	0.5	
34	Acute Right Heart Failure. 2017 , 209-271		
33	Treatment of Pulmonary Hypertension in Interstitial Lung Disease. 2017 , 67-84		
32	A Comparison of Two Different Doses of Sildenafil in Pulmonary Arterial Hypertension [A Prospective Randomised Controlled Study. <i>Journal of Cancer Prevention & Current Research</i> , 2017 , 7,	1.3	
31	Autopsy Findings in A Case of Pulmonary Langerhans Cell Histiocytosis-Associated Pulmonary Hypertension. <i>American Journal of Case Reports</i> , 2017 , 18, 1401-1406	1.3	1
30	Principles of pharmacological correction of pulmonary arterial hypertension. <i>Research Results in Pharmacology</i> , 2018 , 4, 59-76		1
29	Pharmacologic Treatment of IPF. <i>Respiratory Medicine</i> , 2019 , 325-364	0.2	1
28	The Phosphodiesterase-5 Inhibitors and Prostate Cancer [What We Rely Know About It?. <i>Serbian Journal of Experimental and Clinical Research</i> , 2019 ,	0.3	
27	Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases. 2020 , 167-183		
26	Chronic Pulmonary Hypertension. 2020 , 465-489		
25	ERKRANKUNGEN DER ATMUNGSORGANE. 2020 , C-1-C22-4		
24	Immunologische Herzerkrankung. 2006 , 569-580		
23	Acute right ventricular failure from pathophysiology to new treatments. 2006 , 217-228		1
22	Pulmonary hypertension. 160-174		
21	PDE5 Inhibitors and the cGMP Pathway in Pulmonary Arterial Hypertension. 2008 , 305-319		
20	Insuffisance ventriculaire droite. 2006 , 115-130		
19	Immunologische Herzerkrankungen. 2009 , 333-342		1
18	Phosphodiesterase-5 inhibitors. <i>Handbook of Experimental Pharmacology</i> , 2013 , 218, 229-55	3.2	2

17	Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. <i>Texas Heart Institute Journal</i> , 2005 , 32, 405-10	0.8	18
16	Pulmonary hypertension and chronic cor pulmonale in COPD. <i>International Journal of COPD</i> , 2007 , 2, 273-82	3	23
15	Platelets in pulmonary hypertension: a causative role or a simple association?. <i>Iranian Journal of Pediatrics</i> , 2012 , 22, 145-57	1	13
14	Pulmonary Hypertension in Intensive Care Units: An Updated Review. <i>Tanaffos</i> , 2019 , 18, 180-207	0.5	3
13	Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib.. <i>Cells</i> , 2021 , 10,	7.9	0
12	Use of sildenafil in patients with severe COVID-19 pneumonitis.. <i>British Journal of Anaesthesia</i> , 2022 ,	5.4	1
11	Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique Actualisation 2021. Version intégrale. <i>Revue Des Maladies Respiratoires</i> , 2022 ,	0	
10	Federal clinical guidelines on diagnosis and treatment of idiopathic pulmonary fibrosis. <i>Pulmonologiya</i> , 2022 , 32, 473-495	0.8	1
9	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879		18
8	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2021 update. Full-length version. 2022 , 100948		
7	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.		58
6	Chitinase 3-like-1 contributes to the development of pulmonary vascular remodeling in pulmonary hypertension.		0
5	Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study.		1
4	Safety and Feasibility of Riociguat Therapy for the Treatment of Chronic Pulmonary Arterial Hypertension in Infancy. 2022 ,		0
3	Pulmonary Hypertension Association's 2022 International Conference Scientific Sessions Overview.		0
2	Diagnosis and management of pulmonary hypertension related to chronic respiratory disease. 2022 , 18, 220205		0
1	Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease. 2023 , 16, 418		0